vs
Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Ralliant Corp (RAL). Click either name above to swap in a different company.
Ralliant Corp is the larger business by last-quarter revenue ($529.1M vs $493.8M, roughly 1.1× Pediatrix Medical Group, Inc.). Ralliant Corp runs the higher net margin — 7.5% vs 6.8%, a 0.7% gap on every dollar of revenue. On growth, Ralliant Corp posted the faster year-over-year revenue change (-0.5% vs -1.7%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
MD vs RAL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $493.8M | $529.1M |
| Net Profit | $33.7M | $39.9M |
| Gross Margin | — | 50.8% |
| Operating Margin | 9.9% | 9.8% |
| Net Margin | 6.8% | 7.5% |
| Revenue YoY | -1.7% | -0.5% |
| Net Profit YoY | 10.5% | -56.1% |
| EPS (diluted) | $0.40 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $493.8M | — | ||
| Q3 25 | $492.9M | $529.1M | ||
| Q2 25 | $468.8M | $503.3M | ||
| Q1 25 | $458.4M | — | ||
| Q4 24 | $502.4M | — | ||
| Q3 24 | $511.2M | $531.7M | ||
| Q2 24 | $504.3M | $533.7M | ||
| Q1 24 | $495.1M | — |
| Q4 25 | $33.7M | — | ||
| Q3 25 | $71.7M | $39.9M | ||
| Q2 25 | $39.3M | $47.6M | ||
| Q1 25 | $20.7M | — | ||
| Q4 24 | $30.5M | — | ||
| Q3 24 | $19.4M | $90.9M | ||
| Q2 24 | $-153.0M | $64.8M | ||
| Q1 24 | $4.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 50.8% | ||
| Q2 25 | — | 49.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 13.8% | 9.8% | ||
| Q2 25 | 12.8% | 11.7% | ||
| Q1 25 | 7.0% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 6.6% | 20.9% | ||
| Q2 24 | -31.3% | 19.7% | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 6.8% | — | ||
| Q3 25 | 14.5% | 7.5% | ||
| Q2 25 | 8.4% | 9.5% | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 3.8% | 17.1% | ||
| Q2 24 | -30.3% | 12.1% | ||
| Q1 24 | 0.8% | — |
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.84 | $0.35 | ||
| Q2 25 | $0.46 | $0.42 | ||
| Q1 25 | $0.24 | — | ||
| Q4 24 | $0.37 | — | ||
| Q3 24 | $0.23 | $0.81 | ||
| Q2 24 | $-1.84 | $0.57 | ||
| Q1 24 | $0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.2M | $264.2M |
| Total DebtLower is stronger | $570.5M | $1.1B |
| Stockholders' EquityBook value | $865.9M | $3.0B |
| Total Assets | $2.2B | $5.3B |
| Debt / EquityLower = less leverage | 0.66× | 0.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $375.2M | — | ||
| Q3 25 | $340.1M | $264.2M | ||
| Q2 25 | $224.7M | $198.6M | ||
| Q1 25 | $99.0M | — | ||
| Q4 24 | $229.9M | — | ||
| Q3 24 | $103.8M | — | ||
| Q2 24 | $19.4M | — | ||
| Q1 24 | $8.0M | — |
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | $1.1B | ||
| Q2 25 | $583.9M | $1.1B | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $865.9M | — | ||
| Q3 25 | $890.7M | $3.0B | ||
| Q2 25 | $833.8M | $3.0B | ||
| Q1 25 | $789.2M | — | ||
| Q4 24 | $764.9M | — | ||
| Q3 24 | $732.5M | $4.0B | ||
| Q2 24 | $706.5M | $4.0B | ||
| Q1 24 | $856.2M | — |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $5.3B | ||
| Q2 25 | $2.1B | $5.2B | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | 0.39× | ||
| Q2 25 | 0.70× | 0.38× | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.1M | $138.6M |
| Free Cash FlowOCF − Capex | — | $126.6M |
| FCF MarginFCF / Revenue | — | 23.9% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | 3.39× | 3.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.1M | — | ||
| Q3 25 | $137.3M | $138.6M | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $-117.5M | — | ||
| Q4 24 | $133.0M | — | ||
| Q3 24 | $91.8M | — | ||
| Q2 24 | $107.0M | — | ||
| Q1 24 | $-125.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $126.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.39× | — | ||
| Q3 25 | 1.91× | 3.47× | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | -5.66× | — | ||
| Q4 24 | 4.36× | — | ||
| Q3 24 | 4.72× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -31.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
